JANX Latest Press Releases

-- May 7, 2026 --

Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights Business Wire 4:01 PM

-- April 27, 2026 --

Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development Business Wire 4:01 PM

-- April 16, 2026 --

Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014 Business Wire 4:01 PM

-- April 1, 2026 --

Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment Business Wire 8:01 AM

-- February 26, 2026 --

Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Business Wire 4:01 PM

-- February 17, 2026 --

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011 Business Wire 7:00 AM

-- January 26, 2026 --

Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer Business Wire 7:00 AM

-- January 22, 2026 --

Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors Business Wire 7:00 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software